S&P 500   4,567.18
DOW   36,124.56
QQQ   387.29
Investing in quantum computing: A guide 
New CBOE “special perk” helps traders target income every weekend (Ad)
Marvell Technology at a critical pivot: 30% upside is possible
What is dividend harvesting?
New CBOE “special perk” helps traders target income every weekend (Ad)
What analysts wanted out of Chewy stock is finally here
Even Scrooge can’t pass up these 3 bargain stocks
New CBOE “special perk” helps traders target income every weekend (Ad)
The truth about DocuSign's relevancy in today's world: Surprise
SoFi expands ETF business with options-driven income fund
S&P 500   4,567.18
DOW   36,124.56
QQQ   387.29
Investing in quantum computing: A guide 
New CBOE “special perk” helps traders target income every weekend (Ad)
Marvell Technology at a critical pivot: 30% upside is possible
What is dividend harvesting?
New CBOE “special perk” helps traders target income every weekend (Ad)
What analysts wanted out of Chewy stock is finally here
Even Scrooge can’t pass up these 3 bargain stocks
New CBOE “special perk” helps traders target income every weekend (Ad)
The truth about DocuSign's relevancy in today's world: Surprise
SoFi expands ETF business with options-driven income fund
S&P 500   4,567.18
DOW   36,124.56
QQQ   387.29
Investing in quantum computing: A guide 
New CBOE “special perk” helps traders target income every weekend (Ad)
Marvell Technology at a critical pivot: 30% upside is possible
What is dividend harvesting?
New CBOE “special perk” helps traders target income every weekend (Ad)
What analysts wanted out of Chewy stock is finally here
Even Scrooge can’t pass up these 3 bargain stocks
New CBOE “special perk” helps traders target income every weekend (Ad)
The truth about DocuSign's relevancy in today's world: Surprise
SoFi expands ETF business with options-driven income fund
S&P 500   4,567.18
DOW   36,124.56
QQQ   387.29
Investing in quantum computing: A guide 
New CBOE “special perk” helps traders target income every weekend (Ad)
Marvell Technology at a critical pivot: 30% upside is possible
What is dividend harvesting?
New CBOE “special perk” helps traders target income every weekend (Ad)
What analysts wanted out of Chewy stock is finally here
Even Scrooge can’t pass up these 3 bargain stocks
New CBOE “special perk” helps traders target income every weekend (Ad)
The truth about DocuSign's relevancy in today's world: Surprise
SoFi expands ETF business with options-driven income fund

Oncolytics Biotech Stock Price, News & Analysis (TSE:ONC)

C$1.90
+0.01 (+0.53%)
(As of 12/5/2023 ET)
Compare
Today's Range
C$1.86
C$1.91
50-Day Range
C$1.82
C$2.99
52-Week Range
C$1.48
C$4.49
Volume
30,606 shs
Average Volume
110,152 shs
Market Capitalization
C$139.46 million
P/E Ratio
N/A
Dividend Yield
0.31%
Price Target
C$9.00

ONC stock logo

About Oncolytics Biotech Stock (TSE:ONC)

Oncolytics Biotech Inc., a development-stage biopharmaceutical company, focuses on the discovery and development of pharmaceutical products for the treatment of cancer. The company is developing pelareorep, an intravenously delivered immunotherapeutic agent, which is in phase 3 clinical trial for the treatment of hormone receptor-positive / human epidermal growth factor 2-negative metastatic breast cancer and advanced/metastatic pancreatic ductal adenocarcinoma. Oncolytics Biotech Inc. has a co-development agreement with Merck KGaA and Pfizer Inc. to co-develop pelareorep in combination with paclitaxel and Bavencio, a human anti-PD-L1 antibody for the treatment of hormone receptor-positive/human epidermal growth factor 2-negative metastatic breast cancer. The company was incorporated in 1998 and is headquartered in Calgary, Canada.

ONC Stock Price History

ONC Stock News Headlines

How to Invest Early In the Next Potential Breakthrough Nerve-Sensing Technology
Autonomix is preparing a public listing as they develop technology to potentially detect and treat a range of nervous system disorders with much greater visibility than available today. Now, their management team sees a potentially untapped $100B market opportunity.* *Disclosure: This is a paid advertisement for Autonomix’s Regulation A+ Offering. Please read the offering circular at invest.autonomix.com
Oncolytics Biotech's Earnings Outlook
How to Invest Early In the Next Potential Breakthrough Nerve-Sensing Technology
Autonomix is preparing a public listing as they develop technology to potentially detect and treat a range of nervous system disorders with much greater visibility than available today. Now, their management team sees a potentially untapped $100B market opportunity.* *Disclosure: This is a paid advertisement for Autonomix’s Regulation A+ Offering. Please read the offering circular at invest.autonomix.com
Stocks in play: Oncolytics Biotech, Inc.
3 Under-$20 Stocks to Buy for Explosive Returns
JonesTrading downgrades TRACON Pharmaceuticals (TCON) to a Hold
Oncolytics Biotech GAAP EPS of -C$0.12
JonesTrading Remains a Buy on Cassava Sciences (SAVA)
H.C. Wainwright Sticks to Their Buy Rating for Gossamer Bio (GOSS)
See More Headlines
Receive ONC Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Oncolytics Biotech and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings
11/03/2023
Today
12/06/2023
Next Earnings (Estimated)
3/01/2024

Industry, Sector and Symbol

Industry
Biotechnology
Sub-Industry
N/A
Sector
Medical
CIK
N/A
Fax
N/A
Employees
29
Year Founded
N/A

Price Target and Rating

Average Stock Price Target
C$9.00
High Stock Price Target
C$9.00
Low Stock Price Target
C$9.00
Potential Upside/Downside
+373.7%
Consensus Rating
Buy
Rating Score (0-4)
3.00
Research Coverage
3 Analysts

Profitability

Net Income
C$-32,360,000.00
Pretax Margin
N/A

Debt

Sales & Book Value

Annual Sales
N/A
Cash Flow
C$0.45 per share
Book Value
C$0.40 per share

Miscellaneous

Free Float
N/A
Market Cap
C$139.46 million
Optionable
Not Optionable
Beta
1.74
10 "Recession Proof" Stocks That Will Thrive in Any Market Cover

Which stocks are likely to thrive in today's challenging market? Click the link below and we'll send you MarketBeat's list of ten stocks that will drive in any economic environment.

Get This Free Report

Key Executives

  • Dr. Matthew C. Coffey M.B.A.
    Ph.D., President, CEO & Director
  • Mr. Kirk J. Look C.A.
    CA, Chief Financial Officer
  • Mr. Andrew R. de Guttadauro (Age 56)
    Global Head of Business Development & President of Oncolytics Biotech (U.S.) Inc
    Comp: $634.74k
  • Dr. Thomas C. Heineman M.D.
    Ph.D., Chief Medical Officer
  • Ms. Allison Hagerman P.Eng.
    P.M.P., Vice President of Product Development
  • Jon Patton
    Director of Investor Relations & Communication
  • Mr. John Mark Lievonen F.C.A.
    FCA, LLD, Consultant














ONC Stock Analysis - Frequently Asked Questions

Should I buy or sell Oncolytics Biotech stock right now?

3 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Oncolytics Biotech in the last year. There are currently 3 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" ONC shares.
View ONC analyst ratings
or view top-rated stocks.

What is Oncolytics Biotech's stock price target for 2024?

3 brokerages have issued 12-month target prices for Oncolytics Biotech's shares. Their ONC share price targets range from C$9.00 to C$9.00. On average, they predict the company's share price to reach C$9.00 in the next twelve months. This suggests a possible upside of 373.7% from the stock's current price.
View analysts price targets for ONC
or view top-rated stocks among Wall Street analysts.

How have ONC shares performed in 2023?

Oncolytics Biotech's stock was trading at C$2.22 at the beginning of 2023. Since then, ONC shares have decreased by 14.4% and is now trading at C$1.90.
View the best growth stocks for 2023 here
.

When is Oncolytics Biotech's next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Friday, March 1st 2024.
View our ONC earnings forecast
.

How were Oncolytics Biotech's earnings last quarter?

Oncolytics Biotech Inc. (TSE:ONC) issued its quarterly earnings results on Friday, November, 3rd. The company reported ($0.14) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.10) by $0.04.

What other stocks do shareholders of Oncolytics Biotech own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Oncolytics Biotech investors own include Oncolytics Biotech (ONCY), (ONCYF) (ONCYF), Resverlogix (RVX), Ballard Power Systems (BLDP), ProMetic Life Sciences (PLI), Bombardier (BDRBF), Birchcliff Energy (BIR), Enbridge (ENB) and First Majestic Silver (FR).

How do I buy shares of Oncolytics Biotech?

Shares of ONC stock and other Canadian stocks can be purchased through an online brokerage account. Popular online brokerages with access to the Canadian stock market include BMO InvestorLine, CIBC Investor's Edge, Desjardins Online Brokerage, HSBC InvestDirect, Laurentian Bank Discount Brokerage, National Bank Direct Brokerage, Qtrade Investor, Questrade, RBC Direct Investing, Scotia iTrade, TD Direct Investing, and Virtual Brokers.
Compare Top Brokerages Here.

This page (TSE:ONC) was last updated on 12/6/2023 by MarketBeat.com Staff

My Account -